Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 2
Submit an article Journal homepage
106
Views
9
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Alemtuzumab in clinical practice: A British Columbia experience

David Hui Department of Medical Oncology, Vancouver Cancer Centre, Vancouver, BC, Canada
,
Wendy Lam Medical Oncology, Ridge Meadows Hospital, Maple Ridge, BC, Canada
,
Cynthia Toze Bone Marrow Transplant Program, Vancouver General Hospital, Vancouver, BC, Canada
,
Michael Delorme Medical Oncology, Cancer Centre of Southern Interior, Kelowna, BC, Canada
,
Michael Noble Medical Oncology, Royal Columbian Hospital, New Westminister, BC, Canada
,
Paul Klimo Medical Oncology, Lions Gate Hospital, North Vancouver, BC, Canada
,
Judy Sutherland Medical Oncology, Cancer Centre of Southern Interior, Kelowna, BC, Canada
,
Karamjit Gill Medical Oncology, Fraser Valley Cancer Centre, Surrey, BC, Canada
,
Joseph Connors Department of Medical Oncology, Vancouver Cancer Centre, Vancouver, BC, Canada
&
Laurie Sehn Department of Medical Oncology, Vancouver Cancer Centre, Vancouver, BC, CanadaCorrespondence[email protected]
 show all
Pages 218-226 | Received 29 Jun 2007, Accepted 15 Oct 2007, Published online: 01 Jul 2009

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Clive S. Zent. (2008) The role of alemtuzumab in the treatment of chronic lymphocytic leukemia. Leukemia & Lymphoma 49:2, pages 175-176.
Read now

Articles from other publishers (8)

M. Fiegl, R. Stauder, M. Steurer, M. Mian, G. Hopfinger, Y. Brychtova, C. Skrabs, A. Zabernigg, F. Schmid, F. Haslbaur, G. Winder, A. Walder, A. Lang, D. Voskova, R. Greil, J. Mayer & G. Gastl. (2013) Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Annals of Hematology 93:2, pages 267-277.
Crossref
Jeremy L. Warner & Jon E. Arnason. (2012) Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Therapeutic Advances in Hematology 3:6, pages 375-389.
Crossref
Robyn S. Fallen, Collin R. Terpstra & Hermenio C. Lima. (2012) Immunotherapies in Dermatologic Disorders. Medical Clinics of North America 96:3, pages 565-582.
Crossref
Seok Jin Kim, Kihyun Kim, Yong Park, Byung Soo Kim, Jooryung Huh, Young Hae Ko, Keunchil Park, Cheolwon Suh & Won Seog Kim. (2010) Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Investigational New Drugs 30:1, pages 368-375.
Crossref
Michael Fiegl, Florian Falkner, Michael Steurer, Niklas Zojer, Georg Hopfinger, Ferdinand Haslbauer, Guntram Winder, Daniela Voskova, Johannes Andel, Alois Lang, Yvona Brychtova, Jiri Mayer, Richard Greil & Günther Gastl. (2011) Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Annals of Hematology 90:9, pages 1083-1091.
Crossref
M. Fiegl, M. Erdel, I. Tinhofer, Y. Brychtova, A. Panovska, M. Doubek, K. Eigenberger, C. Fonatsch, G. Hopfinger, H. Mühlberger, A. Zabernigg, F. Falkner, G. Gastl, J. Mayer & R. Greil. (2010) Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Annals of Oncology 21:12, pages 2410-2419.
Crossref
Michael Fiegl & Jiri Mayer. 2010. Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy, and Prognosis 343 358 .
M. Fiegl, G. Gastl, G. Hopfinger, K. Eigenberger, A. Zabernigg, T. Schenk, F. Falkner, A. Falkner, S. Sodia, M. Doubek, Y. Brychtova, A. Panovska, R. Greil & J. Mayer. (2008) Alemtuzumab in chronic lymphocytic leukaemia, other lymphoproliferative disease and autoimmune disorders. memo - Magazine of European Medical Oncology 1:4, pages 211-222.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.